Marty Tenenbaum, PhD Founder of Cancer Commons

  • December 23, 2022  

    10 Things I Learned in 10 Years at Cancer Commons That Could Save Your Life

    With: Marty Tenenbaum, PhD

    After facing his own cancer, Marty Tenenbaum, PhD, founded Cancer Commons to help others dealing with the disease. Here, Curious Dr. George asks him to share what he has learned. Curious Dr. George: As a well-known survivor of metastatic melanoma, and as the founder of Cancer Commons, you are often sought out by friends and acquaintances who have just been diagnosed with cancer or… Read more »

  • October 8, 2020  

    Pediatric Cancer: The “Day One Talk” Bookmark

    Marty Tenenbaum, PhD

    Article from the Journal of Clinical Oncology, curated by Cancer Commons founder Marty Tenenbaum, PhD.

    This piece discusses a “method of delivering bad news to parents of children with cancer in hopes that our approach may be helpful to others and may spur discussion.”

    .

  • July 16, 2018  

    Proposed FDA “Conditional Approval”- More Details

    With: Marty Tenenbaum, PhDAl Musella, DPM

    A Q&A with Al Musella, DPM, President, Musella Foundation For Brain Tumor Research & Information, Inc., Hewlett, NY, and Marty Tenenbaum, PhD, Founder and Chair, Cancer Commons, Los Altos, CA Originally published May 10, 2017 Q: Your April 5, 2017 blog post that proposed a new “Conditional” category for FDA drug approval elicited a number of positive and negative responses. Please explain the proposal in more detail… Read more »

  • July 2, 2018  

    A Proposed New FDA Drug Approval Pathway: “Conditional”

    With: Marty Tenenbaum, PhDAl Musella, DPM

    A Q&A with Al Musella, DPM, President, Musella Foundation For Brain Tumor Research & Information, Inc., Hewlett, NY, and Marty Tenenbaum, PhD, Founder and Chair, Cancer Commons, Los Altos, CA Originally published April 5, 2017 Q: The delay time from discovery/observation, through validation to approval and distribution/use of new cancer treatments remains excessive. With promising experimental treatments, advanced computer technology and biostatistics, creative alternatives… Read more »